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Abstract 
Analyses of microRNA (miRNA) expression signatures obtained by RNA sequencing 
revealed that some passenger miRNAs (miR-144-5p, miR-145-3p, miR-149-3p, miR-150-3p and 
miR-199a-3p) acted as anti-tumor miRNAs in several types of cancer cells. The involvement of 
passenger strands in the pathogenesis of human cancer is a novel concept. Based on the miRNA 
signature of bladder cancer (BC) obtained by RNA sequencing, we focused on both strands of 
the miR-223-duplex (miR-223-5p and miR-223-3p) and investigated their functional significance 
in BC cells. Ectopic expression of these miRNAs showed that both miR-223-3p (the guide 
strand) and miR-223-5p (the passenger strand) inhibited cancer cell migration and invasion of 
BC cells. The role of miR-223-5p (the passenger strand) has not been well studied. Combining 
gene expression studies and in silico database analyses, we demonstrated the presence of 20 
putative target genes that could be regulated by miR-223-5p in BC cells. Among these targets, 
high expression of 5 genes (ANLN, INHBA, OIP5, CCNB1 and CDCA2) was significantly 
associated with poor prognosis of BC patients based on The Cancer Genome Atlas (TCGA) 
database. Moreover, we showed that a gene (ANLN) encoding a multifunctional actin-binding 
protein was directly regulated by miR-223-5p in BC cells. Overexpression of ANLN was 
observed in BC clinical specimens and high expression of ANLN was significantly associated 
with poor prognosis of BC patients. 
We suggest that studies of regulatory cancer networks, including the passenger strands of 
miRNAs, may provide new insights into the pathogenic mechanisms of BC. 
 
 
Keywords: miR-223-5p, miR-223-3p, microRNA, miRNA duplex, bladder cancer, ANLN, anti-
tumor, passenger strand 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Bladder cancer (BC) is a commonly diagnosed urologic cancer that constitutes the ninth 
most common cause of cancer-related death worldwide.1 In 2015, it was estimated that 
approximately 76,000 new cases of BC were diagnosed and 1,600 patients died in the United 
States of America.2 Approximately 70–80% of patients are categorized with non-muscle–
invasive BC (NMIBC) at the first diagnosis and high relapse rates (50%-70%) are observed in 
patients with NMIBC.3, 4 Unfortunately, more than 15% of recurrent BC patients develop  
muscle–invasive BC (MIBC); the 5-year survival rate for patients with MIBC is approximately 
60%.5 At present, there are no effective therapeutic strategies for patients with lymph node and 
distant metastasis or failure of first-line treatment.6 Therefore, elucidation of the molecular 
pathogenesis underlying the acquisition of MIBC phenotypes and identification of therapeutic 
targets are urgent issues that must be addressed to improve the poor prognosis of BC patients. 
MicroRNAs (miRNAs) belong to a group of small non-coding RNA molecules that act as 
pivotal agents responsible for fine-tuning RNA expression in a sequence-dependent manner.7, 8 
The unique nature of miRNA is that a single miRNA species might control the expression of a 
large number of protein-coding (or noncoding) genes in normal or diseased cells.9 Thus, 
abnormal expression of miRNAs can disrupt RNA networks and can lead to human diseases.10-15 
There is substantial evidence that dysregulated miRNAs are deeply involved in the development 
of cancer cells, as well as their metastasis and drug resistance.11-16 We have been analyzing anti-
tumor miRNAs in BC based on miRNA signatures to clarify their contribution to BC 
pathogenesis.17-19 
The general concept of miRNA biogenesis posits that the passenger strand of miRNA (the 
minor strand or miRNA*) derived from duplex miRNA is degraded and does not regulate gene 
expression.20, 21 Contrary to this theory, construction of miRNA signatures by RNA sequencing 
revealed that some miRNA passenger strands (miR-144-5p, miR-145-3p, miR-149-3p, miR-150-
3p and miR-199a-3p) were downregulated in several cancers compared with normal tissues.17, 22-
24   Our previous studies of BC revealed that miR-144-5p and miR-139-3p possessed anti-
tumor roles through targeting of CCNE1/2 and MMP11, respectively.18, 25 These facts have 
changed the concept of miRNA biogenesis and demonstrated the importance of analyzing 
miRNA passenger strands in cancer. 
In this study, we focused on both strands of the miR-223 duplex, i.e., miR-223-5p, the 
passenger strand and miR-223-3p, the guide strand. We used miRNA signatures to investigate 
their anti-tumor roles and determine the relevant oncogenic networks in BC cells. We suggest 
that identification of novel function of passenger strands of miRNAs and the RNA networks 
they regulate might enhance our understanding of the molecular pathogenesis of BC. 
 
 Materials and Methods 
Human tissue samples and BC cell lines 
Clinical tissue samples (BC and normal tissues) were collected from patients who 
underwent total cystectomy or nephroureterectomy at Chiba University Hospital between 2014 
and 2015. The characteristics of the patients with BC are summarized in Supplemental Table 1. 
Written informed consent was obtained from all patients who were told the outline of the study 
and the use of the samples for scientific research. The protocol of this study was approved by 
the Institutional Review Board of Chiba University; approval number is 484. 
In this study, we used 2 human BC cell lines, BOY and T24. The BOY cell line was 
established at Kagoshima University and was derived from a male Asian patient. The T24 cell 
line was obtained from the American Type Culture Collection. Details of the 2 cell lines were 
described previously.26, 27 
 
Transfection of mature miRNAs and small interfering RNAs (siRNAs) 
The following molecular reagents were used for functional assays: mature miRNAs, 
mature miRNA precursors (hsa-miR-223-5p, assay ID: PM 12672; hsa-miR-223-3p, assay ID: 
PM 12301; Applied Biosystems, Foster City, CA, USA), miRNA control (assay ID: AM 17111; 
Applied Biosystems), and siRNA (Stealth Select RNAi siRNA; si-ANLN P/N: HSS122893 and 
HSS182497; Invitrogen, Carlsbad, CA, USA). The procedures for transfecting these small 
RNAs into cancer cell lines have been described.26, 27 
 
Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) 
To measure the expression of miR-223-5p, miR-223-3p and ANLN in normal tissues, 
cancer tissues and cell lines, the following procedures and reagents were used. For quantitative 
RT-PCR (qRT-PCR) we utilized P/N: 002098 (Applied Biosystems) for miR-223-5p and P/N: 
002295 for miR-223-3p. To assess ANLN, we used an assay-on-demand gene expression product 
(P/N: Hs01122612_m1; Thermo Fisher Scientific). To normalize the data, we used human 
GUSB (P/N: Hs99999908_m1; Applied Biosystems), GAPDH (P/N: Hs02758991_m1; Applied 
Biosystems) and RNU48 (assay ID: 001006; Applied Biosystems). The qRT-PCR procedures 
were described earlier.26, 27 
 
Functional assays for cell proliferation, migration, and invasion 
The procedures for assessment of cell proliferation, migration and invasion have been 
described.26, 27 
 
Preparation of the miRNA-incorporated fraction by Ago2 immunoprecipitation 
We investigated whether the passenger strand of miRNA (miR-223-5p) was actually 
incorporated into the RNA-induced silencing complex (RISC). Immunoprecipitation was 
carried out using a human Ago2 miRNA isolation kit (Wako, Osaka, Japan) in order to purify 
miRNA-incorporated fractions after miR-223-5p or miR-223-3p transfection. The procedure was 
carried out according to the manufacturer’s protocol.28 
 
Western blot and Immunohistochemistry analysis 
Antibodies used in this experiment were mouse monoclonal anti-ANLN antibodies (1:750 
dilution; AMAb90662; Atlas Antibodies AB, Stockholm, Sweden). Anti-glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) antibodies (1:10000 dilution; ab8245; Abcam, Cambridge, 
UK) were used as an internal control. The procedures for Western blot analysis were described 
previously.26, 27 
Tissue samples were incubated overnight at 4°C with anti-ANLN antibodies diluted 1:50 
(AMAb90662; Atlas Antibodies AB) and anti-Ki67 antibodies diluted 1:50 (sc-15402; Santa 
Cruz Biotechnology, Santa Cruz, CA, USA). The procedure for immunohistochemistry was 
described previously.26, 27 
 
Identification of the putative oncogenic targets of miR-223-5p or miR-223-3p in BC cells 
Oncogenic genes specifically affected by miR-223-5p or miR-223-3p in BC cells were 
identified by using a combination of in silico database and genome-wide gene expression 
analyses. TargetScan database (release 7.1) was used for prediction of putative targets of these 
miRNAs. Upregulated genes in BC clinical specimens were analyzed in Gene Expression 
Omnibus (GEO) data sets (accession numbers GSE 31684 and GSE 11783). Our original gene 
expression data for miR-223-5p or miR-223-3p transfected cells were deposited in GEO 
database (accession number GSE 107008). Strategies for identifying miRNA targeted genes 
were described previously.22, 29 
 
Dual-luciferase reporter assays and vector construction 
The wild-type or deletion-type sequences targeted by miR-223-5p were inserted in the 
psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). After co-transfecting miR-223-5p 
and the constructed vector in T24 cells, firefly and Renilla luciferase activities were measured. 
Renilla luciferase intensity (Renilla/firefly) was expressed as normalized data. The procedure 
for dual-luciferase reporter assays was described in our previous studies.26, 27 
 
The Cancer Genome Atlas (TCGA) database analysis of BC samples 
To investigate the clinical significance of the expression status of ANLN in BC patients, 
we analyzed TCGA datasets (The Cancer Genome Atlas: https://tcga-data.nci.nih.gov/tcga/). A 
large amount of cohort data was retrieved from cBioPortal (http://www.cbioportal.org/) and 
OncoLnc (data downloaded on November 1, 2017). Detailed information on the method is 
described in a previous paper.26, 27 
 
Statistical analysis 
The relationships between 2 groups were analyzed using Mann-Whitney U tests. The 
relationships between three variables and numerical values were analyzed using Bonferroni-
adjusted Mann-Whitney U tests. Spearman’s rank tests were used to evaluate the correlation 
between the expression of miR-223-5p and miR-223-3p. Data analyses were performed using 
Expert StatView software, version 5.0 (Cary, NC, USA). Overall survival and disease-free 
survival of patients were estimated using the Kaplan-Meier method and log-rank tests with JMP 
PRO software (version 13; SAS Institute Inc., Cary, NC, USA). 
 
 
Results 
Expression levels of miR-223-5p and miR-223-3p in BC clinical specimens and cell lines 
We evaluated the expression levels of miR-223-5p and miR-223-3p in 15 paired BC 
tissues and their matched adjacent non-cancer tissues. The results showed that the expression 
levels of miR-223-5p and miR-223-3p were signiﬁcantly lower in BC tissues than in adjacent 
noncancerous epithelium (P < 0.0001; Fig. 1A). In BOY and T24 cells, the expression of miR-
223-5p and miR-223-3p was somewhat lower than non-cancerous clinical specimens (Fig. 1A).  
In clinical specimens, a positive correlation between the expression levels of miR-223-5p 
and miR-223-3p was found by Spearman’s rank test (P < 0.0001; Fig. 1B). 
 
Investigation of the anti-tumor roles of miR-223-5p and miR-223-3p in BC cells 
To evaluate the anti-tumor roles of both strands of the miR-223-duplex (miR-223-5p and 
miR-223-3p), we applied gain-of-function assays using mature miRNA restoration into two BC 
cell lines (BOY and T24). 
Cancer cell proliferation was reduced by restoration of miR-223-5p and miR-223-3p in 
BC cells compared to mock or miR-control transfected cells (Fig. 1C). Likewise, cancer cell 
migration and invasion abilities were significantly suppressed by restoration of miR-223-5p and 
miR-223-3p in BC cells (Figs. 1D and 1E). These findings suggested that both strands of miR-
223-5p and miR-223-3p acted as anti-tumor miRNAs in BC cells. 
 
Incorporation of both strands of the miR-223 duplex into RISC in BC cell 
We investigated whether both strands of the miR-223 duplex were actually functional in 
BC cells. The illustration of restored miRNAs incorporated into the RISC is shown in 
Supplemental Fig. 1. We carried out immunoprecipitation with antibodies targeting Ago2, which 
plays pivotal roles in the RISC. After mature miRNA transfection, we performed qRT-PCR to 
assess whether transfected miRNA was actually bound to Ago2. After transfection with miR-
223-5p as a passenger strand and immunoprecipitation by anti-Ago2 antibodies, miR-223-5p 
levels were significantly higher than those of mock- or miR-control-transfected cells and those 
of miR-223-3p-transefected T24 cells (P < 0.0001; Supplemental Fig. 1). 
 
Regulation of putative oncogenic targets by miR-223-5p and miR-223-3p in BC cells 
Our strategy for identifying target oncogenes of miR-223-5p and miR-223-3p is shown in 
Supplemental Fig. 2. First, putative target genes of miR-223-5p were identified using the 
TargetScan database, leading us to 3,164 genes. Next, we carried out genome-wide gene 
expression analysis using a microarray comparing miR-223-5p- transfected and mock 
transfected T24 cells (accession number: GSE 107008). As a result, a total of 2,556 genes were 
downregulated (log2 ratio < 0). Among these genes, we searched for genes that were upregulated 
in BC cells (log2 fold-change > 3), using publicly available gene expression data sets in GEO 
(accession number: GSE 31684 and GSE 11783). As a result, we identified 20 candidate target 
genes of miR-223-5p (Table 1A). 
Using The Cancer Genome Atlas (TCGA) database, we investigated patient survival rates 
as a function of high or low expression levels of these genes. Among them, CCNB1 had the 
greatest effect on overall survival, but ANLN was higher in GEO log fold-change data (Figs. 2A 
and 2B). Therefore, we focused on ANLN as a candidate gene of miR-223-5p (see below). Using 
a similar approach, we found that 26 genes were candidate targets of miR-223-3p regulation 
(Table 1B). 
 
Direct regulation of ANLN by anti-tumor miR-223-5p in BC cells 
We confirmed that gene expression of ANLN was significantly decreased in BC cells 
transfected with miR-223-5p compared to the mock or miR-control BC cell lines (P < 0.001; 
Fig. 3A). Western blotting analyses revealed that ANLN protein levels of miR-223-5p- 
transfected BC cells were decreased compared to mock or miR-control BC cell lines (Fig. 3B). 
On the other hand, the expression of ANLN was not reduced in miR-223-3p transfected BC cell 
lines at either the mRNA level or protein level (Figs. 3A and 3B). 
Next, we performed luciferase reporter assays to determine whether miR-223-5p directly 
targeted the 3′-UTR region of ANLN. According to the TargetScan Human database, the binding 
site for miR-223-5p in the 3′-UTR of ANLN consisted of a single region (positions 1007-1013; 
Fig. 3C). We showed that miR-223-5p suppressed reporter activity of ANLN wild-type vector 
transfectants compared to mock or miR-control transfectants, whereas transfectants of the 
deletion type vector were not decreased (Fig. 3D). 
 
Effects of knockdown of ANLN in BC cells 
To assess the effect of ANLN in BC cells, loss-of-function assays using siRNA were 
performed. We evaluated the knockdown efficiency of si-ANLN-transfected BC cell lines. 
Downregulation of ANLN/ANLN was detected in si-ANLN transfectants (Figs. 4A and 4B).  
Cancer cell proliferation, migration and invasion abilities were significantly blocked in si-
ANLN transfectants compared to those in mock or miR-control transfected BC cell lines (Figs. 
4C-4E).  
 
Expression of ANLN/ANLN in BC clinical specimens and its clinical significance 
The mRNA levels of ANLN were upregulated in 15 BC tissues compared to adjacent 
noncancerous tissues (P < 0.01; Fig. 5A). To investigate the relationship between ANLN 
expression and clinical features, we searched the TCGA database. Kaplan–Meier analysis 
showed that the high ANLN expression group had a significantly lower disease-free survival 
compared to the low ANLN expression group (P = 0.01; Fig. 5B). The histologically poor grade 
group was higher in ANLN expression (P < 0.0001; Fig. 5C). 
Finally, we carried out immunostaining analyses of clinical specimens to evaluate ANLN 
protein expression. Immunostaining analyses revealed that ANLN was more strongly expressed 
in the BC clinical specimens than in the non-cancer specimens. Notably, ANLN was expressed 
at higher levels in the nuclei of the BC specimens. We also performed immunostaining of Ki67. 
The cells showing nuclear staining for ANLN were also positive for Ki67 (Fig. 5D). Therefore, 
it appeared that ANLN was expressed abundantly in the cancerous regions where cell 
proliferation was active. 
 
 
Discussion 
It is generally believed that only guide strands of miRNAs are incorporated into the RISC 
and control target gene expression.30 Our original RNA sequencing-based miRNA expression 
signatures revealed that some passenger strands of miRNAs might be involved in cancer 
pathogenesis. This finding expands the number of miRNAs to be studied in cancer pathology 
research. For example, our recent studies showed that miR-145-3p (a passenger strand of the 
miR-145-duplex) had anti-tumor roles, as did miR-145-5p in several cancers.19, 23, 31, 32 In 
prostate cancer (PCa), expression of anti-tumor miR-145-3p was significantly reduced in 
castration-resistant PCa specimens, and its targeted genes (MELK, NCAPG, BUB1, and CDK1) 
predicted survival in such patients.23 More recently, we confirmed that miR-145-3p possessed 
anti-tumor functions through its targeting of several oncogenes in head neck cancer.32 
Our present data showed that both strands of the miR-223-duplex (miR-223-5p and miR-
223-3p) were downregulated in BC tissues and that these miRNAs had anti-tumor roles. The 
anti-tumor functions of miR-223-3p (guide strand) were reported in several cancers, such as 
breast and cervical cancers.33, 34 In contrast, oncogenic function of miR-223-3p was reported by 
several cancers, T-cell acute lymphoblastic leukemia and gastric cancer.35 Our previous study of 
PCa showed that miR-223-3p was significantly reduced in naïve PCa specimens and that ectopic 
expression of miR-223-3p significantly inhibited cancer cell migration and invasion.36 
Moreover, our study found that expression of integrin α3 (ITGA3) and β1 (ITGB1) was directly 
regulated by miR-223-3p in PCa cells.36 Interestingly, both ITGA3 and ITGB1 were 
overexpressed in PCa tissues and knockdown of these integrins inhibited cancer cell 
aggressiveness through reduced downstream oncogenic signaling.36 Strategies to block integrin-
mediated oncogenic signaling might lead to new cancer treatments.  
Previous studies showed that several transcription factors and oncogenes have been 
identified as miR-223-3p regulation in several cancer cell and disease cells.35, 37, 38  In our 
present study of miR-223-3p target genes, some genes, e.g., E2F1, SMARCD1, RHOB, SOX11 
and PAX6, have been reported as miR-223-3p regulation in previous reports. 35, 37-42 This 
indicates that our miRNA target search strategy is reliable. Interestingly, overexpression of 
E2F1, a master transcriptional factor contributed to MIBC progression and its expression was 
significantly associated with EZH2 and SUZ12 expression.43, 44 Moreover, overexpression of 
E2F1/EZH2/SUZ2 enhanced cancer cell migration, invasion and colony formation.43, 44 From 
these things, screening for miR-223-3p or miR-223-5p targets could provide effective 
information for BC treatment. 
To elucidate the involvement of both miR-223-5p and miR-223-3p in BC pathogenesis, 
we analyzed the molecular targets regulated by these molecules. In the present study, we 
identified 20 putative target genes regulated by miR-223-3p (the guide strand) and 26 by miR-
223-5p (the passenger strand) in BC cells. Among these target genes (46 genes), high expression 
levels of 8 genes (ANLN, INHBA, OIP5, CCNB1, CDCA2, KIF4A, ECT2 and RHOB) were 
associated with poor prognosis of BC patients. Analysis of these genes is important for deeper 
understanding of the molecular pathogenesis of BC. We focused on ANLN because its 
expression was regulated by miR-223-5p and its expression was deeply associated with poor 
prognosis of BC by a large number of cohort analyses. 
Based on its sequence, it has been predicted that ANLN has multiple functions, such as an 
actin-binding, myosin-binding and pleckstrin-homology domains.45 ANLN is localized 
primarily in the nucleus during interphase; in telophase, it moves to the cytoplasm and forms the 
contractile ring and cleavage furrow.46 Overexpression of ANLN enhances the metastatic 
potential of several types of cancer cells, including lung, breast and colon cancers.47-49 Recent 
study of pancreatic adenocarcinoma (PDAC) showed that knockdown of ANLN significantly 
inhibited cancer cell migration and invasion.50 Moreover, Kaplan–Meier survival curves showed 
that high expression of ANLN predicted shorter survival of patients with PDAC based on TCGA 
dataset analysis.50 More recently, ANLN was identified as a frequently overexpressed gene in 
BC by RNA sequencing and its expression is a promising prognostic biomarker in this disease.51 
These studies and our present data showed that aberrantly expressed ANLN acted as a pivotal 
player for BC cell aggressiveness and metastasis.51 Exploration of novel anti-tumor miR-233-
5p-mediated pathways may lead to the development of new treatment protocols for this disease. 
Previous studies indicated that expression of ANLN was directly regulated by miR-217 and miR-
497 in pancreatic cancer and nasopharyngeal carcinoma, respectively.50, 52 It would be necessary 
to investigate the involvement of these miRNAs in BC pathogenesis. 
In conclusion, both strands of the miR-223-duplex, miR-223-5p (the passenger strand) and 
miR-223-3p (the guide strand), acted as anti-tumor miRNAs through their targeting of several 
oncogenic genes in BC cells. ANLN, a gene encoding a multifunctional actin-binding protein 
was directly regulated by miR-223-5p. Overexpression of ANLN was involved in the 
pathogenesis of BC and acted as an oncogene. The anti-tumor function of the passenger strand 
of miRNA is a new concept in cancer research and searching for molecular mechanisms 
controlled by passenger strands of miRNA is a new challenge in studies of BC pathogenesis. 
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Figure Legends 
Figure 1. Expression levels of miR-223-5p and miR-223-3p in BC clinical specimens and 
cell lines: functional analyses of those miRNAs in BC cells. 
(A) Quantitative real-time RT-PCR showed that the expression levels of miR-223-5p and miR-
223-3p were significantly lower in BC tissues than in normal bladder tissues. Expression in 2 
BC cell lines, BOY and T24, was lower than in normal bladder tissues. RNU48 was used as an 
internal control. (B) Correlations among the relative expression levels of miR-223-5p and miR-
223-3p. (C-E) Effects of restoration of miR-223-5p and miR-223-3p in BC cells. Cell 
proliferation (72 h after transfection with 10 nM miRNA) and migration and invasion (48 h after 
transfection with 10 nM miRNA) were characterized after transfection with miR-223-5p of miR-
223-3p. *,P < 0.0001; **, P = 0.001 
 
Figure 2. Kaplan–Meier plots of overall survival versus expression of the candidate genes 
regulated by miR-223-5p and miR-223-3p in BC cells. 
The Cancer Genome Atlas (TCGA) database was used to analyze putative targets of miR-223-5p 
(A) and miR-223-3p (B) in BC. Kaplan-Meier plots of overall survival with log-rank tests for 8 
genes with high and low expression in the BC TCGA database. 
 
Figure 3. Direct regulation of ANLN by miR-223-5p in BC cell lines. 
(A) ANLN mRNA expression in BC cell lines was evaluated by qRT-PCR 72 h after transfection 
with miR-223-5p. GUSB was used as an internal control. *, P < 0.0001. (B) ANLN protein 
expression in BC cell lines was evaluated by Western blot analyses 72 h after transfection with 
miR-223-5p. GAPDH was used as a loading control. (C) miR-223-5p binding sites in the 3′-
UTR of ANLN mRNA. Dual luciferase reporter assays using vectors encoding putative miR-
223-5p target sites (positions 1007-1013) of the ANLN 3′-UTR for both wild-type and deleted 
regions. Normalized data were calculated as ratios of Renilla/firefly luciferase activities. *, P < 
0.005. 
 
Figure 4. Effects of ANLN silencing in BC cell lines. 
(A) ANLN mRNA expression in BC cell lines was evaluated by qRT-PCR 72 h after transfection 
with si-ANLN-1 or si-ANLN-2. GUSB was used as an internal control. (B) ANLN protein 
expression in BC cell lines was evaluated by Western blot analysis 72 h after transfection with 
si-ANLN-1 or si-ANLN-2. GAPDH was used as a loading control. (C) Cell proliferation was 
determined with the XTT assays 72 h after transfection with 10 nM si-ANLN-1 and si-ANLN-2. 
*,P < 0.0001. (D) Cell migration activity was determined by migration assays. *,P < 0.0001. (E) 
Cell invasion activity was determined using Matrigel invasion assays. *, P < 0.0001. 
 Figure 5. Expression levels of ANLN mRNA and immunohistochemical staining of ANLN 
protein in BC specimens. 
(A) Expression levels of ANLN mRNA in BC or normal bladder tissues and BC cell lines. (B) 
The high ANLN expression group had significantly lower disease-free survival. p = 0.01 (C) The 
relation between the pathological grade of BC and ANLN expression. The high grade BC group 
shows higher ANLN expression. *, P < 0.0001. (D) Immunohistochemical staining of ANLN 
and Ki67 in BC specimens. 
 
Supplemental Figure 1. Incorporation of miR-223-5p and miR-223-3p into the RNA-
induced silencing complex (RISC) in T24 cells. 
(A) Mature microRNA was transfected into T24 cells where it was incorporated into the RISC. 
The incorporated microRNA was prepared to high purity using immunoprecipitation with anti-
human Ago2 monoclonal antibody. Expression of the microRNA was quantified with RT-PCR. 
(B) Expression of miR-223-5p was significantly higher than that in cells transfected with mock, 
miR control or miR-223-3p. P < 0.0001.  (C) Expression of miR-223-3p was significantly 
higher than that in cells transfected with mock, miR control or miR-223-5p. *, P < 0.0001.  
 
Supplemental Figure 2. Flow chart illustrates the strategy for analysis of miR-223-5p and 
miR-223-3p in BC cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
83540 NUF2 NUF2, NDC80 kinetochore complex component -3.12 1 5.43 0.7700
23397 NCAPH non-SMC condensin I complex, subunit H -0.12 1 5.02 0.7950
54443 ANLN anillin, actin binding protein -1.90 1 4.54 0.0155*
4312 MMP1 matrix metallopeptidase 1 (interstitial collagenase) -2.52 1 4.44 0.8340
8838 WISP3 WNT1 inducible signaling pathway protein 3 -0.34 1 4.39 0.1620
3624 INHBA inhibin, beta A -0.94 4 4.36 0.042*
8287 USP9Y ubiquitin specific peptidase 9, Y-linked -0.43 1 3.94 0.3760
147841 SPC24 SPC24, NDC80 kinetochore complex component -1.49 1 3.92 0.2130
7546 ZIC2 Zic family member 2 -0.11 1 3.62 0.0617
11339 OIP5 Opa interacting protein 5 -1.51 2 3.58 0.0185*
6374 CXCL5 chemokine (C-X-C motif) ligand 5 -0.93 1 3.57 0.4910
11130 ZWINT ZW10 interacting kinetochore protein -2.58 1 3.48 0.9210
9837 GINS1 GINS complex subunit 1 (Psf1 homolog) -2.22 2 3.22 0.9500
79801 SHCBP1 SHC SH2-domain binding protein 1 -3.05 1 3.20 0.9180
9768 KIAA0101 KIAA0101 -1.56 1 3.18 0.6540
891 CCNB1 cyclin B1 -1.59 1 3.12 0.0035*
157313 CDCA2 cell division cycle associated 2 -1.98 1 3.12 0.0336*
8357 HIST1H3H histone cluster 1, H3h -1.21 1 3.09 0.6550
6913 TBX15 T-box 15 -1.02 3 3.05 0.7180
4085 MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) -1.89 2 3.03 0.7380
6326 SCN2A sodium channel, voltage gated, type II alpha subunit -0.89 1 3.48 0.7310
25769 SLC24A2 solute carrier family 24 (sodium/potassium/calcium exchanger), member 2 -0.94 1 3.47 0.5200
121355 GTSF1 gametocyte specific factor 1 -0.75 1 3.39 0.5140
115111 SLC26A7 solute carrier family 26 (anion exchanger), member 7 -0.53 1 2.55 -
7545 ZIC1 Zic family member 1 -0.55 1 2.53 0.9960
1894 ECT2 epithelial cell transforming 2 -0.62 1 2.52 0.0281*
1869 E2F1 E2F transcription factor 1 -1.34 1 2.36 0.4350
10675 CSPG5 chondroitin sulfate proteoglycan 5 (neuroglycan C) -0.55 1 2.34 0.6760
149018 LELP1 late cornified envelope-like proline-rich 1 -1.70 1 2.33 0.9900
284403 WDR62 WD repeat domain 62 -1.27 1 2.15 0.7240
64137 ABCG4 ATP-binding cassette, sub-family G (WHITE), member 4 -0.59 1 1.85 -
2057 EPOR erythropoietin receptor -0.59 1 1.85 -
6602 SMARCD1
SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily d, member 1
-0.03 1 1.81 0.7570
79838 TMC5 transmembrane channel-like 5 -0.58 1 1.76 0.6120
374407 DNAJB13 DnaJ (Hsp40) homolog, subfamily B, member 13 -0.66 1 1.73 0.2850
6323 SCN1A sodium channel, voltage gated, type I alpha subunit -0.76 1 1.72 0.5620
6579 SLCO1A2 solute carrier organic anion transporter family, member 1A2 -0.58 1 1.24 0.6460
403314 APOBEC4 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 4 (putative) -1.28 1 1.24 0.2480
23160 WDR43 WD repeat domain 43 -0.51 1 1.23 -
27173 SLC39A1 solute carrier family 39 (zinc transporter), member 1 -0.87 1 1.15 -
388 RHOB ras homolog family member B -0.53 1 1.14 0.00755*
24137 KIF4A kinesin family member 4A -1.56 1 1.13 0.0186*
81610 FAM83D family with sequence similarity 83, member D -0.51 1 1.06 0.109
5996 RGS1 regulator of G-protein signaling 1 -0.28 1 1.03 0.261
6664 SOX11 SRY (sex determining region Y)-box 11 -1.21 1 1.01 0.314
5080 PAX6 paired box 6 -1.27 1 1.01 0.27
GEO
Log2 FC
(A)  miR ‑223-5p
* Poor prognosis with a high expression
Table 1 Candidate target genes regulated by miR ‑223-5p  and miR-223-3p  in BC.
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No. Age Sex T N M operation method neoadjuvant therapy pathology grade remarks
1 51 M a 0 0  nephroureterectomy - Urothelial Carcinoma 3 RT-PCR
2 61 M a 0 0  cystectomy - Urothelial Carcinoma 2 RT-PCR
3 65 M 1 0 0  nephroureterectomy - Urothelial Carcinoma 3 RT-PCR
4 67 M 2 0 0  nephroureterectomy - Urothelial Carcinoma 3 RT-PCR
5 67 M 3b 0 0  cystectomy GCBDCA 4 course Urothelial Carcinoma 3 RT-PCR
6 70 M 2b 0 0  cystectomy GC 2 course Urothelial Carcinoma 3 RT-PCR / IHC
7 72 M 2 0 0  cystectomy MVAC 2 course Urothelial Carcinoma 3 RT-PCR
8 72 F 3 0 0  nephroureterectomy - Urothelial Carcinoma 2 RT-PCR
9 73 F 3 0 0  nephroureterectomy - Urothelial Carcinoma 3 RT-PCR
10 74 F 3 0 0  nephroureterectomy - Urothelial Carcinoma 3 RT-PCR
11 78 F 2 0 0  nephroureterectomy - Urothelial Carcinoma 3 RT-PCR
12 80 F 1 0 0  nephroureterectomy - Urothelial Carcinoma 3 RT-PCR
13 81 M 2 0 0  nephroureterectomy - Urothelial Carcinoma 3 RT-PCR
14 81 M 3 0 0  nephroureterectomy - Urothelial Carcinoma 2 RT-PCR
15 81 M 3 0 0  nephroureterectomy - Urothelial Carcinoma 3 RT-PCR
16 68 F 1 0 0  cystectomy GC 2 course Urothelial Carcinoma 2 IHC
GCBDCA: Gemcitabine Carboplatin; GC: Gemcitabine Cisplatin;  MVAC: Methotrexate Vinblastine Doxorubicin Cisplatin
Supplemental Table 1. Clinical features of patients
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Journal of Human Genetics  Vol.63  No.5 
doi:10.1038/s10038-018-0437-8 
https://www.nature.com/articles/s10038-018-0437-8 
平成 30年 3月 14日 公表済 
